Tumour necrosis factor-α inhibitors have a growing role in managing late-onset ankylosing spondylitis and spondylarthritis

Author：  

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.27, Iss.2, 2011-02, pp. : 13-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Late-Onset Ankylosing Spondylitis and Spondylarthritis: An Update on Clinical Manifestations, Differential Diagnosis and Pharmacological Therapies

By Toussirot Éric  

Drugs & Aging, Vol. 27, Iss. 7, 2010-07 ,pp. : 523-531

Adis International

Access to resources Recommend Favorite

Use NSAIDs to relieve pain and stiffness in patients with ankylosing spondylitis and reserve tumour necrosis factor-α antagonists for NSAID-refractory patients

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 5, 2006-05 ,pp. : 11-14

Adis International

Access to resources Recommend Favorite

Structure-Modifying Capacity of Anti-Tumour Necrosis Factor- Therapy in Ankylosing Spondylitis

By Filip De Keyser   Baeten Dominique   Filip Van den Bosch   Kruithof Elli   Verbruggen Gust   Mielants Herman   Veys Eric  

Drugs, Vol. 64, Iss. 24, 2004-01 ,pp. : 2793-2811

Adis International

Access to resources Recommend Favorite

Tumour necrosis factor-α inhibitors/immunosuppressants: Cancer: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1423, 2012-01 ,pp. : 48-48

Adis International

Access to resources Recommend Favorite

The Case of Tumour Necrosis Factor-α Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis

By Sørensen Jan  

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 289-298

Adis International

Access to resources Recommend Favorite